IBogen International retains Shine Nyquist as capital markets advisor

Calgary, dadAnd April 29, 2022 /CNW/ – Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (“user interface“or the”company”) advises a life sciences company that aims to develop and deliver ibogaine-centric medical addiction treatment care that it has retained Mr. Shine Nyquist In an advisory role as a capital markets advisor.

Universal Ibogaine appoints Shayne Nyquvest as capital markets advisor (CNW Group/Universal Ibogaine Inc.)

Mr. Nyquvest has extensive experience in the capital markets, with over 40 years of involvement in strategic corporate fundraising activities, in mining, hemp and other emerging industries. He served as the former Executive Vice President of investment banking firm Mackie Research Capital (where he worked June 2015 to July 2018) and was a founding member of the Canaccord Genuity Group, where he served as a senior investment advisor from 1993 to 2013.

Mr. Nyquvest co-founded UI in early 2018, having personally seen the transformative effects and potential of ibogaine and was involved in the development of early-stage UI through mid-2021. His vision was to see this innovative plant-based treatment embraced by the mainstream medical community as a solution to help with Ending the opioid epidemic and other addictions.

Nick CarusUi CEO, UI noted, “We are delighted to re-engage Shayne in our strategic business development goals. He has an extensive network in the investment community and has been instrumental in early-stage UI funding and research activities. As we continue to develop our blueprint, Health Canada clinical trials apply to the use of ibogaine. on opioid use disorder and we expect to provide additional updates on this in the near future.”

About Universal Ibogaine Inc.

UI is a life sciences company, whose mission is to demonstrate the safety and efficacy of an ibogaine-based detox protocol through a planned Canadian clinical trial (focusing on opioid use disorder), and ultimately the worldwide use of that protocol through licensing future planned agreements. UI is concurrently developing the latest comprehensive addiction treatment protocol at its Kelburn Recovery Center, which, when paired with a planned ibogaine detoxification protocol, aims to revolutionize the way we treat addiction and improve the lives of individuals and families affected by addiction. .

Neither the TSX VENTURE EXCHANGE nor the Regulatory Services Provider (as this term is defined in the TSX Project Exchange Policies) accepts responsibility for the adequacy or accuracy of this release.

Cautionary statement regarding forward-looking statements

This press release may contain forward-looking statements and information. Forward-looking information is often characterized by phrases such as “plans,” “expects,” “project,” “intends,” “will,” “believe,” “expect,” “estimate,” “scheduled,” “potential,” or other words. Similar, or phrases implying that some event or circumstance “may,” “should,” or “could” occur. Forward-looking statements and information are based on certain key expectations and assumptions made by the user interface. Although UI believes that the expectations and assumptions on which forward-looking statements are based are reasonable, you should not place undue reliance on forward-looking statements because UI can provide no guarantee that they will prove correct.

Because forward-looking statements address future events and conditions, they inherently involve inherent risks and uncertainties. Actual results may differ materially from those currently projected due to a number of factors and risks, including, but not limited to, risks not obtained from required regulatory approvals. The reader is cautioned that assumptions used in preparing such information, although considered reasonable by the user interface at the time of preparation, may prove incorrect and readers are cautioned against undue reliance on forward-looking information, which speaks only to the terms as of the date of this Law. User Interface undertakes no obligation to publicly disclose any revisions to the forward-looking information contained herein to reflect events or circumstances occurring after the date of this Contract or to reflect the occurrence of unforeseen events, except as may be required by applicable securities laws.

Cision

Cision

View original content for multimedia download:

SOURCE Universal Ibogaine Inc.

Cision

Cision

View the original multimedia download content: http://www.newswire.ca/en/releases/archive/April2022/29/c1023.html

Leave a Comment